Has Samuel Banks, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,864 in general payments to Samuel Banks, MD across 560 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samuel Banks, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samuel Banks, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samuel Banks, MD

Dermatology · Chattanooga, TNNPI 1801995329

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 560 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations.

$10,864in general payments, 2019–2025

Across 560 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$1K
Novartis$1K
Sanofi$1K
Regeneron Healthcare Solutions, Inc.$1K
UCB, Inc.$969
AbbVie$958
plus $4K from 27 others

What the payments were for

Food & beverage$10,56997%
Education$2943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	81	$1,460
Novartis	91	$1,458
Sanofi	42	$1,099
Regeneron Healthcare Solutions, Inc.	39	$1,002
UCB, Inc.	44	$969
AbbVie	59	$958
Sun Pharmaceutical Industries Inc.	41	$754
Johnson & Johnson	25	$600
Amgen	22	$445
VYNE Pharmaceuticals Inc.	12	$264
Incyte Corporation	12	$214
Genentech USA, Inc.	13	$209
Dermavant Sciences, Inc.	8	$168
Galderma Laboratories, L.p.	9	$146
Ortho Dermatologics, A Division Of Bausch Health US, LLC	8	$141
LEO Pharma Inc.	8	$135
Pfizer	6	$123
Arcutis Biotherapeutics, Inc.	7	$121
E.r. Squibb & Sons, L.L.C.	7	$121
Smith+Nephew	3	$62
Organogenesis Inc.	2	$51
Boehringer Ingelheim	2	$45
Kerecis Limited	3	$45
Almirall LLC	2	$44
Mylan Institutional Inc.	2	$36
Dermira, Inc.	2	$35
Bristol Myers Squibb	2	$34
Organon	2	$29
Prugen, Inc. Pharmaceuticals	2	$21
Mayne Pharma Commercial LLC	1	$20
Mallinckrodt Enterprises LLC	1	$19
Integra Lifesciences Corporation	1	$19
Cipher Pharmaceuticals US LLC	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$234
COSENTYX$223

How this compares

$10,864 in reported general payments places this provider in the 80th percentile of 209 dermatology providers in Tennessee.

See all dermatology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$511,591

Medicare patients

662

Services billed

4,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	27	$191,031
Cosentyx Sensoready (2 Pens)Secukinumab	16	$115,807
Clobetasol Propionate	132	$4,891
Fluorouracil	54	$3,909
Ketoconazole	62	$1,151
Triamcinolone Acetonide	141	$1,053
Doxycycline Hyclate	36	$833
Metronidazole	15	$575
Mupirocin	50	$355
Finasteride	46	$302
Ammonium Lactate	18	$237
Fluticasone Propionate	13	$154
Hydrocortisone	31	$129
MethotrexateMethotrexate Sodium	13	$119
Minoxidil	22	$113

Paid to pharmacies, not to this prescriber.

Other dermatology in Chattanooga

Cara HenningsChattanooga$15K
Laura ClearyChattanooga$13K
Kimberly VincentNashville$1.5M
Adrian RodriguezNashville$1.1M
Michael GoldNashville$748K
Joni SagoKingsport$661K
Jennifer LeeBrentwood$396K
Christina FeserClarksville$383K
Emily OverholserMemphis$322K
James TurnerBartlett$314K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →